Status:
COMPLETED
Dexmedetomidine for Attenuation of Pressor Response
Lead Sponsor:
Theodor Bilharz Research Institute
Conditions:
Pressor Response
Eligibility:
All Genders
18-60 years
Phase:
PHASE4
Brief Summary
Direct laryngoscopy and tracheal intubation are usually associated by hemodynamic changes due to increased sympathoadrenal activity which could precipitate serious negative effects in compromised pati...
Detailed Description
Various drugs include local anesthetics, beta-blockers, calcium channel blockers, and narcotic analgesics have been tried to blunt the laryngoscopy and intubation response, with varied success. Dexmed...
Eligibility Criteria
Inclusion
- 1 - ASA physical status 1-2. 2. Age 18- 60 years old of both sexes. 3. Patients undergoing elective surgery under general anesthesia and tracheal intubation.
Exclusion
- Age \< 18 years and ≥ 60 years
- Pregnancy
- Emergency surgery or full stomach
- Renal or Hepatic patients
- Patients with suspected difficult airway {e.g., high neck circumference, high body mass index (above 30 kg/m2), airway masses, mouth scars, neck scars, limited neck extension or history of snoring.
- Total duration of laryngoscopy will be noted and in cases where duration exceeded 15 sec the case will be excluded from the study.
- Any patient on regular intake of beta blockers or calcium channel blockers
- Patients with any known hypersensitivity or contraindication to dexmedetomidine,
- Patients with significant neurological, psychiatric, or neuromuscular disorders.
Key Trial Info
Start Date :
February 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 30 2024
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06592027
Start Date
February 1 2024
End Date
May 30 2024
Last Update
September 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Theodor Bilharz Research institute
Giza, Egypt, 02